← back to search

Anja Baumann

University of Vienna · AT
Area of research
Epidemiology · Hematology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Multiple Myeloma Research and Treatments, Diet, Metabolism, and Disease, and Diet and metabolism studies.
h-index
24
citations
1,512
works
106
NIH funding
primary concept
email

Recent publications

Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma
Cells 2024cited by 12position: middledoi
Resolving therapy resistance mechanisms in multiple myeloma by multiomics subclone analysis
Blood 2023cited by 59position: middledoi
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level
Nature Communications 2023cited by 35position: middledoi
Cognitive Alterations in Old Mice Are Associated with Intestinal Barrier Dysfunction and Induced Toll-like Receptor 2 and 4 Signaling in Different Brain Regions
Cells 2023cited by 13position: middledoi
OA-23 Resolving therapy resistance mechanisms in multiple myeloma by multi-omics subclone analysis
Clinical Lymphoma Myeloma & Leukemia 2023cited by 2position: middledoi
Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
Frontiers in Oncology 2022cited by 13position: middledoi
Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
Blood 2022cited by 4position: middledoi
Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single‐cell transcriptomics
Nature Communications 2021cited by 133position: middledoi
Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease
Scientific Reports 2021cited by 27position: firstdoi
The Spatial Heterogeneity in Newly Diagnosed Multiple Myeloma Patients - from Sub-Clonal Architecture to the Immune Microenvironment
Blood 2021cited by 6position: middledoi
OAB-007: Single-cell multiomic analysis identifies regulatory programs in relapsed/refractory multiple myeloma
Clinical Lymphoma Myeloma & Leukemia 2021cited by 1position: middledoi
Targeting PI3K-AKT-mTOR Signaling in Multiple Myeloma Mesenchymal Stem Cells Mediates Antiproliferative Effect on Myeloma Cells
Blood 2021cited by 1position: middledoi
P-049: The spatial sub-clonal architecture in newly diagnosed myeloma patients revealed by whole genome and single-cell sequencing
Clinical Lymphoma Myeloma & Leukemia 2021cited by 0position: middledoi
P-060: Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single cell transcriptomics
Clinical Lymphoma Myeloma & Leukemia 2021cited by 0position: middledoi
HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
Molecular Cancer Therapeutics 2020cited by 76position: middledoi
Comprehensive Comparison of Early Relapse and End-Stage Relapsed Refractory Multiple Myeloma
Blood 2020cited by 9position: middledoi
A Comprehensive Analysis of Single-Cell Chromatin Accessibility and Gene Expression Identifies Intra-Tumor Heterogeneity and Molecular Treatment Responses in Relapsed/Refractory Multiple Myeloma
Blood 2019cited by 2position: middledoi
Dissecting Heterogeneity of Tumor Cells and Their Microenvironment in Refractory Multiple Myeloma
Blood 2019cited by 1position: middledoi
HDP-101: Preclinical evaluation of a novel anti-BCMA antibody drug conjugates in multiple myeloma.
Journal of Clinical Oncology 2018cited by 13position: middledoi
Preclinical Evaluation of Hdp-101, a Novel Anti-BCMA Antibody-Drug Conjugate, in Multiple Myeloma
Blood 2017cited by 14position: middledoi
IgE-dependent activation of human mast cells and fMLP-mediated activation of human eosinophils is controlled by the circadian clock
Molecular Immunology 2014cited by 25position: firstdoi
The circadian clock is functional in eosinophils and mast cells
Immunology 2013cited by 104position: firstdoi
Substantially Improved Outcome of Adult Burkitt Non-Hodgkin Lymphoma and Leukemia Patients with Rituximab and a Short-Intensive Chemotherapy; Report of a Large Prospective Multicenter Trial
Blood 2012cited by 10position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Marc S. Raab · Memorial Sloan Kettering Cancer Center16 papers (2017–2024)Carsten Müller‐Tidow · Heidelberg University13 papers (2017–2023)Hartmut Goldschmidt · Virginia Cooperative Extension13 papers (2017–2023)Alexandra M. Poos · German Cancer Research Center12 papers (2019–2023)Lukas John · University of Hohenheim11 papers (2019–2024)Niels Weinhold · Sylvester Comprehensive Cancer Center11 papers (2019–2024)Katharina Bauer · German Cancer Research Center9 papers (2019–2023)Stephan M. Tirier · German Cancer Research Center9 papers (2019–2023)Nicola Giesen · Robert Bosch Hospital9 papers (2019–2023)Karsten Rippe · Hopp Children's Cancer Center Heidelberg9 papers (2019–2023)Jan‐Philipp Mallm · German Cancer Research Center8 papers (2019–2023)Oliver Stegle · Institut thématique Génétique, génomique et bioinformatique7 papers (2019–2023)Simon Steiger · German Cancer Research Center7 papers (2021–2023)Stefanie Huhn · Heidelberg University6 papers (2020–2023)Nina Prokoph · German Cancer Research Center5 papers (2021–2023)Hana Sušak · German Cancer Research Center4 papers (2019–2021)Nicola Casiraghi · German Cancer Research Center4 papers (2019–2021)Moritz J. Przybilla · German Cancer Research Center4 papers (2019–2023) · 3 papers (2017–2020)Philipp Reichert · Heidelberg University3 papers (2023–2024)